Cover Image

Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: neue Marker und Technologien

Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, no...

Full description

Saved in:
Bibliographic Details
Main Authors: Warth, Arne (Author) , Endris, Volker (Author) , Kriegsmann, Mark (Author) , Stenzinger, Albrecht (Author) , Penzel, Roland (Author) , Pfarr, Nicole (Author) , Weichert, Wilko (Author)
Format: Article (Journal)
Language:German
Published: 28. März 2015
In: Der Pathologe
Year: 2015, Volume: 36, Issue: 2, Pages: 154-163
ISSN:1432-1963
DOI:10.1007/s00292-015-0004-4
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s00292-015-0004-4
Verlag, Volltext: https://link.springer.com/article/10.1007/s00292-015-0004-4
Get full text
Author Notes:A. Warth, V. Endris, M. Kriegsmann, A. Stenzinger, R. Penzel, N. Pfarr, W. Weichert
Description
Summary:Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.
Item Description:Gesehen am 27.09.2017
Physical Description:Online Resource
ISSN:1432-1963
DOI:10.1007/s00292-015-0004-4

Similar Items